Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CFO Anna Mowry Purchases 15,000 Shares

Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) CFO Anna Mowry purchased 15,000 shares of the company's stock in a transaction dated Thursday, May 29th. The stock was purchased at an average price of $0.77 per share, for a total transaction of $11,550.00. Following the completion of the purchase, the chief financial officer now owns 83,000 shares in the company, valued at approximately $63,910. The trade was a 22.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Nautilus Biotechnology Trading Down 3.6%

Nautilus Biotechnology stock traded down $0.03 during trading on Thursday, reaching $0.75. The company had a trading volume of 91,166 shares, compared to its average volume of 119,401. Nautilus Biotechnology, Inc. has a 52 week low of $0.66 and a 52 week high of $3.09. The firm's 50-day simple moving average is $0.76 and its 200 day simple moving average is $1.37. The firm has a market capitalization of $94.25 million, a price-to-earnings ratio of -1.33 and a beta of 1.43.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last posted its quarterly earnings results on Tuesday, April 29th. The company reported ($0.13) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.01. On average, analysts predict that Nautilus Biotechnology, Inc. will post -0.57 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. Geode Capital Management LLC boosted its position in shares of Nautilus Biotechnology by 0.6% during the fourth quarter. Geode Capital Management LLC now owns 1,142,542 shares of the company's stock valued at $1,920,000 after buying an additional 7,000 shares during the period. Palumbo Wealth Management LLC boosted its position in shares of Nautilus Biotechnology by 45.4% during the fourth quarter. Palumbo Wealth Management LLC now owns 28,475 shares of the company's stock valued at $48,000 after buying an additional 8,888 shares during the period. SG Americas Securities LLC boosted its position in shares of Nautilus Biotechnology by 56.3% during the fourth quarter. SG Americas Securities LLC now owns 27,483 shares of the company's stock valued at $46,000 after buying an additional 9,904 shares during the period. Bank of America Corp DE boosted its position in shares of Nautilus Biotechnology by 37.1% during the fourth quarter. Bank of America Corp DE now owns 49,419 shares of the company's stock valued at $83,000 after buying an additional 13,363 shares during the period. Finally, Virtu Financial LLC purchased a new position in shares of Nautilus Biotechnology during the fourth quarter valued at approximately $28,000. Hedge funds and other institutional investors own 50.71% of the company's stock.

Analysts Set New Price Targets

Separately, Guggenheim set a $2.50 target price on Nautilus Biotechnology in a report on Friday, February 28th.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.